Introduction
Cystic fibrosis (CF) is the most common life-shortening genetic disease, with an incidence of 1 in 2500 and carrier frequency of 1 in 25, among Caucasians [1] . With recent advances in treatment, most children with CF now can expect to survive into adulthood and life expectancy has improved considerably. CF is a progressive disease that affects many organ systems. As the disease progresses, patients require more intensive health care that includes home-based care, medications, more frequent and prolonged hospital admissions, and, in around half of all cases, lung transplantation [2, 3] . With the advent of new and improved treatment options, the patterns of care have changed and this has had an impact on both health care costs and patient outcomes. For example, two of the key medications developed in the last 15 years, dornase alfa (Pulmozyme) and tobramycin (Tobi), cost around US $10,000 per annum and more sophisticated technology, such as gene-based treatments, may be even more expensive. Ever increasing pressures on health care budgets mean that health care decision makers are expected to require evidence on the cost-effectiveness of new treatments before funding is approved.
Cost-effectiveness analysis requires a sound understanding of the long-term costs of care for CF. In particular, information on how treatment costs are altered when disease progression is slowed would be a valuable input to future economic analysis. The aim of this study was to provide researchers with estimates of the long-term costs and consequences of CF progression. Such estimates will be of particular value to policymakers and evaluators who wish to examine the potential cost impact of new technologies. The results reported in this study will allow shortterm clinical trial results to be extrapolated over the longer term.
Previous Literature
There have been a small number of studies that examined the cost of care associated with CF. A systematic review identified eight cost-of-illness studies, but only five of these were based on individual patient care data, with the other three based on cost estimates provided by clinical experts [4] . We have identified four further studies that were published after the Krauth et al. [4] review. Table 1 summarizes each of the studies that were based on patient data. The average annual health care cost ranged from US $8,148 to US $50,723 (in constant 2009 dollars). Some studies found considerable cost variation among patients with CF depending on the patient's lung function, whereas others found no significant effect. For example, the study by Lieu et al. [10] found that the average annual health care cost for a patient with poor lung function was seven times greater than for a person with relative good lung function status. A more recent study by DeWitt et al. [14] found that baseline lung function score was not a significant predictor of health care costs.
These studies have been limited by their data. The small sample size of all studies (ranging from 65 to 352) limits their ability to examine differences in the cost among different population groups. For example, the study by Baumann et al. [8] relied on children's resource use data to estimate costs of adult patients. Other studies were limited by the scope of the data collection. For example, Horvais et al. [12] included out-ofhospital costs but did not have data on inpatient treatments and Heimeshoff et al. [11] focused on patients treated in one center. Consequently, these studies are limited in their ability to provide an overall assessment of the lifetime health care costs for the entire CF population.
Our study is based on the Australian Cystic Fibrosis Data Registry (ACFDR). The longitudinal nature of this data allows us to estimate the rate of CF progression, and its large sample size allows us to calculate the rate of disease progression for various age groups and health states as well as the health care costs associated with treating CF. The results from the transition and cost analysis are then combined to arrive at the estimated lifetime costs of CF.
Methods

Data
Three years of data from the ACFDR were used (2003, 2004, and 2005) , with de-identified data from participants that can be linked across these years. The ACFDR includes information on clinical measures, mortality, demographics, complications, and health care resource use. For more information on the ACFDR, including descriptive analysis and data items, see the reports published by Cystic Fibrosis Australia [15, 16] .
Estimating Transitional Probabilities to Model Disease Progression
The ACFDR contains data on the forced expiratory volume in 1 second as a percentage of predicted volume (FEV 1 %)-a standard measure of lung function. Severity of lung disease is the key to the quality and length of life [17] of patients with CF. The best recorded FEV 1 % measure in each year was used to classify health states. We chose the FEV 1 % cutoff scores for severity states 1, 2, and 3 on the basis that these were consistent with a previous US study that examined the cost of CF care [10] . We generated a separate category for patients who had received a lung transplant because these patients require medications and health care services that are in addition to standard CF care [18] . For this reason, transplant patients were assumed to remain in health state 4 unless a death was recorded. Death is the fifth and absorbing health state. Patients can therefore progress through five health states, defined as follows: Heimeshoff et al. [11] uk/costconversion/default.aspx); blank values, not stated.
observations were excluded in calculating transition probabilities (n ¼ 877). Generally, lung function tests cannot be performed by children younger than 8 years. We therefore combined health states 1, 2, and 3 for this age group. By using data from the ACFDR, we employed a Markov approach to estimate the annual probability of disease progression for patients with CF. Figure 1 illustrates the disease progression model. Figure 1A shows the model for children younger than 8 years, and Figure 1B shows the model for everyone else. A discrete time transition matrix was calculated for each age group, allowing transition probabilities to vary as the cohort moves from one age group to the next. The probabilities were estimated on the basis of the number of patients in a given health state in the second observation, conditional on their health state in the first observation. We used a constant annual cycle length to model disease progression and used the life table solution to compensate for the underestimation of state membership that occurs in a discrete Markov process [19] .
Each patient observation was assigned to 1 of 14 age groups. Each age group represents 3 years, with the exception of the last age group, which represents all those aged 38 years and older, and the third age group, representing children aged 6 and 7 years. We chose the maximum number of age groups while ensuring that each group contained at least 30 patients and that each age group Sources. a ¼ DOHA [20] ; b ¼ Cystic Fibrosis NSW [24] ; c ¼ online pharmacy; d ¼ Government of Western Australia [25] . CF, cystic fibrosis.
represented a similar number of years. The annual transition probabilities vary between age groups but not within an age group. For the purpose of modeling CF transitions, the disease was assumed to be progressive, meaning that patients could not improve their health state. The data showed that out of 2255 patients, 83 patients contradicted this assumption and improved their FEV 1 % score and thereby also improved their health state. After we allowed a margin of error of 10% in the cutoff scores for health states 1, 2, and 3, only nine patients still improved their health state. For the purposes of ensuring a progressive disease model, we deleted these nine records from the transition probability calculations.
Resource Use and Unit Costs Data
The ACFDR contains resource use data on the number of CFrelated hospitalizations in a year, the prescription medications administered, types of dietary supplements used, number of clinical visits, use of oxygen therapy, and some pathology tests. In addition, data exist on whether a patient has undergone a lung transplant and on death status. Resource use for medicines and pathology tests is reported as a binary value in the ACFDR, indicating whether a particular patient is consuming a type of medication or has undertaken a test that year. The clinical authors (J.M. and M.D.) supplemented the ACFDR data by providing the drug names typically used in the management of CF as well as information on the typical number of scripts required per year. In some instances, the type of drug and the number of scripts depend on the age of the patients. These variations have been incorporated into the analysis.
Unit cost information was obtained from standard Australian sources that are routinely used in economic evaluations: the National Hospital Cost Data Collection, the Pharmaceutical Benefits Schedule for all prescription drug costs, and the Medicare Benefits Schedule for medical consultations and diagnostic test costs [20] [21] [22] [23] . Where necessary, these were supplemented by cost information from the literature [24] [25] [26] [27] . [21] . CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator; IV, intravenous; MBS, Medicare Benefits Schedule. Table 2 lists the unit prices for each CF-related medicine identified in the ACFDR. In most instances, CF-related medicines are listed on the Pharmaceutical Benefits Schedule, which entitles patients to a government subsidy, although they may still face co-payments. Unit prices include the cost to government and patient. Some CF-related medicines such as vitamins are not listed on the Pharmaceutical Benefits Schedule, and patients have to pay the full amount out of their own pocket. Table 3 lists the unit prices for each of the CF-related medical services, procedures, and hospitalizations that are identified in the ACFDR. In most instances, CF-related services are subsidized by Australia's universal Medicare program. Based on clinical advice, a clinical visit comprises consultations with a specialist medical practitioner and three allied health care workers, which may include nutritionists, physiotherapists, and social workers and nurses.
Cost Analysis
For each patient, a total annual health care cost was estimated on the basis of the individual patient's resource use for that year. For each age group, health care costs were aggregated for four out of five health states. No costs could be incurred after death. The immediate costs associated with transplants were based on the Australian National Hospital Cost Data Collection [21] . To obtain an annualized cost, the cost of transplant surgery was divided by the difference between the patient's age at surgery and the maximum age in the data set (47 years). Thus, the average annual surgery cost increases as the age of the patient at the time of the transplant increases. Ongoing health care costs for transplant patients, incurred postsurgery, were estimated by using data from the ACFDR.
The lifetime costs were estimated on the basis of the sum of the expected costs for each year of life, as set out in Equation 1:
where P is the probability of a patient with CF at age a, and in health state s, and C is the discounted annual health care costs of managing a patient with CF. The main lifetime cost results are based on a life expectancy of 47 years. We chose this cutoff point because this was the age of the oldest patient in the data set. As a test of sensitivity, however, we also report the lifetime cost up to age 65 years. Future health care costs were discounted at 0%, 3.5%, and 5%. Because of the skewness of cost data, we report both mean and median costs for each health state and age group. In addition, we estimated a 95% confidence interval of mean costs by using a bootstrap method. The confidence intervals were estimated on the basis of 2000 replications for each age group and health state. The lower and upper bounds of the interval were used in the sensitivity analysis for the lifetime cost analyses.
The perspective taken in this analysis is that of the health care system. While this approach ignores important patient and family costs associated with the disease (such as lost productivity by parents and patients as well as travel costs associated with receiving care), it is consistent with most economic evaluations in health care and is certainly advocated by Australian guidelines on health economic evaluation and elsewhere [28] . Wherever possible, we have attempted to use the overall health system costs including contributions made by thirdparty payers (usually government) as well as out-of-pocket costs incurred by patients for prescription drugs. All costs reported use 2009 price levels and, where necessary, prices have been adjusted by using the Australian Bureau of Statistics' Consumer Price Index [29] . All currencies have been converted to US dollars by applying OECD GDP purchasing power parities (PPP) conversion rates and using the Campbell and Cochrane Economics Methods Group (CCEMG) -Evidence for Policy and Practice Information and Co-ordination (EPPI)-Centre Cost Converter (see http://eppi.ioe.ac.uk/costconversion/default.aspx for more details). The PPP conversion rate used in this study was US $1 is equal to AU $1.45.
Results
Transitional Probabilities
The three waves of ACFDR data provided 4032 transition records from 2255 individual patients. Patients with FEV 1 % data in all three waves (n ¼ 1623 patients) provided two transition records (i.e., the probabilities of transition from first-year data to the second-year data and from the second to the third year). For patients with an FEV 1 % observation in the first and third years (2003 and 2005), we linearly extrapolated the FEV 1 % lungfunction score for the second year and then allocated a health state accordingly (n ¼ 154). These patients also provided two transition records. A further 478 patients provided FEV 1 % observation in two subsequent ACFDR years. These observations were used to calculate one transition record. Those patients who died during the observation period but had no prior FEV 1 % values recorded were assumed to have suffered from severe disease prior to death (health state 3). Table 4 shows the baseline patient characteristics for the 2255 patients in the sample used to calculate transitions. The mean age was 15 years, and slightly more than half the sample was male. The average FEV 1 % score for those aged 8 years and older was 78.6, indicating that the mean health state is mild disease. Around one third of the sample was aged 8 years or younger, and only 6% of the patients were older than 37 years.
The transitional probabilities for disease progression for each of our five health states are reported in Table 5 
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0.997 0.000 0.003
0.973 0.027 0.000 0.000 0.000 Note. Lung function cannot be identified in the data for children aged younger than 8 y and therefore health states 1, 2, and 3 were aggregated for this group of patients. Absolute patient numbers are available on request to the corresponding author. CF, cystic fibrosis.
is an annual 2.7% chance that a patient will move from health state 1 to 2. Figure 2 illustrates how, over time, the cohort progress from one health state to another. At age 45 years, the model predicts that approximately two-thirds of the cohort have died, approximately 10% have received a transplant, and 1%, 15%, and 8% are in health states 1, 2, and 3, respectively.
Resource Use
To estimate cost and resource use, we include all observations in the registry with an identifiable health state. The sample for this part of the analysis consisted of 3149 patients providing 5938 observation records. This is larger than the transition probabilities sample size because patients had to provide only one health CFTR, cystic fibrosis transmembrane conductance regulator; IV, intravenous.
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state record (instead of at least two) to be included in the cost analysis. Table 6 provides a summary of the proportion of patients who are consuming medicines identified in the CF registry data as well as tests and medical services. The use of some medicines such as antibiotics appears to be stable across health states, but the use of most treatments rises as the disease progresses. Tests such as cystic fibrosis transmembrane conductance regulator analysis and sweat chloride tests are undertaken more often when patients are in the early severity stages of CF. This is an indication that such tests are used for the initial CF diagnosis. Table 7 summarizes the annual number of medical services used by patients with CF according to their severity. On average, patients in health state 1 were admitted to hospital for 6.1 days for CF-related purposes. This number rises to 24.9 days for those in health state 3 and falls to 17.5 days for those who have undergone transplant surgery, although it should be noted that this does not include the days spent in the hospital for the actual transplant surgery. Table 8 shows the annual health care costs associated with the management of CF and associated complications for each age group and health state. The mean, bootstrapped standard error, and median are presented. Overall, the mean annual cost associated with CF management is US $15,571, with a 95% confidence interval range of US $15,032 to US $16,110. For health states combined, annual health care costs decline somewhat after age 2 years, then generally rise until patients reach their early thirties, then plateau at around US $20,000 to US $25,000 per year. Based on the standard errors reported in Table 8 , the decrease in health care after age 2 years is statistically significant, as are the increases in the teenage years. The overall median health care cost is US $6,233 per year and ranges from US $2,269 for children aged 6 to 7 years to US $16,704 for 26-to 28-year-old patients. The difference between the mean and median statistics indicates that health care costs are highly skewed. This is not unusual in health care cost data where a small number of patients are very high users of health care resources and thereby greatly influence mean costs.
Annual Costs
Both mean and median costs rise significantly as the disease progresses from health state 1 to 3. For all ages combined, when patients progress from health state 1 to 2, both mean and median health care costs increase by around US $15,000. While the average annual cost for health state 4 (patients who have received a transplant) is higher than that for health state 3, the difference is not statistically significant. The median cost for health state 4 is slightly lower than that for health state 3.
Cost by Health Care Sector Figure 3 illustrates the distribution of total costs by main health care sector for each health state. The figure demonstrates that Lifetime Costs and Total Health System Cost Table 9 presents the results on lifetime health care costs up to age 47 years. Two estimates based on mean and median annual costs are produced. As a large proportion of health care costs is incurred in future years, it is appropriate that a discount rate is applied. Table 9 presents results where future health care costs are discounted at 0%, 3.5%, and 5% per year after the first year. Using a 3.5% discount rate, mean and median lifetime health care costs are estimated to be around US $306k and US $190k, respectively. If we were to run the model up to age 65 years, the mean (median) lifetime health care costs are estimated to be $320k ($200k) applying a 3.5% discount rate. On the basis that there are around 3000 patients with CF in Australia, the annual health system costs is in the vicinity of US $47 million.
Conclusions
We have successfully developed a model of CF disease progression to estimate the cost of medical care for people with CF. The mean annual cost for managing patients with CF is US $15,571, with a lifetime cost of US $306k. The health care costs rise as a patient's disease progresses. Average costs for patients with severe disease were three times higher than those for patients with mild disease. This indicates that potential new therapies that can delay disease progression may have important costoffsets that need to be incorporated in economic evaluations. There are several limitations in this study. First, the scope of ACFDR is not complete. Patients with CF who do not attend one of the participating treatment centers will not be captured by the data. Although a recent report by Cystic Fibrosis Australia estimates that its registry now captures around 90% of all patients [30] , the percentage was lower in the data available for this study. Second, coverage of the CF registry in terms of resource use is also not complete. As a result, some health care costs such as general practitioner attendances are not included in the analysis. Similarly, CF registry data may not be comprehensive in capturing resource use associated with CF-related complications such as diabetes and liver disease. We have tried to overcome such gaps by using cost evidence from other studies, but these tend to be estimated on a population basis. It may well be the case that this is an underestimate of the true costs. This is because the cost of treating complications among patients with CF may be higher than the cost of treating similar complications in those who do not have CF and are otherwise healthy. These issues could be addressed by linking ACFDR with administrative data sets that provide detailed information on health care use and costs. The ACFDR would be further enhanced by seeking quality-of-life information from patients and carers. The addition of qualityof-life data and improved resource use data would make the ACFDR a powerful tool for future analysis, and a truly unique 
asset in Australia. This data set can be used to undertake important economic and outcomes research. Third, the analysis uses only 3 years of registry data, limiting our ability to examine disease progression over a longer period of time. Cystic Fibrosis Australia is currently undertaking work to enable more linkage across waves. When this work is complete, it will allow researchers to utilize the panel structure of the data more fully. Finally, there was a large number of missing FEV 1 % values in the ACFDR. These are most likely due to issues of data collection, rather than patient selection. Despite these high numbers, our sample captures around 80% of the CF population. As children cannot generally perform the required lung function test, FEV 1 % values are also missing for those younger than 8 years. As a result, we made an assumption about these children's health states. An important area for future research will be to model disease progression among the very young by using alternative markers of severity [31] .
Notwithstanding these limitations, our results appear to be consistent with earlier research. Our assumption that CF is a strictly progressive disease (i.e., lung function does not improve) after taking into account patients who had undergone transplant surgery also appears to be validated by the data. Our estimate, in terms of mean annual costs, is less than those found in some studies but greater than the mean costs found in the 1996 Canadian study by Johnson et al. [6, 12, 13, 32] . Care should be taken in comparing these results because there are differences in methodologies and patient groups. For example, Eidt-Koch et al. [13] focused only on outpatient medication costs and the patient group studied in Heimeshoff et al. [11] was older and suffered more severe disease compared with the group in the present study. The results of the current study are similar to those reported by Robson et al. [5] , Ireys et al. [7] , and Lieu et al. [10] . In the case of Lieu et al. [10] , the median costs are also similar to those in the present study.
This study makes a number of important contributions to the existing literature. It is the first analysis to develop a model of disease progression and thereby estimate lifetime costs, by using longitudinal registry data. Second, this study has used a much larger sample size than previous studies, enabling us to estimate costs on the basis of age and severity. Third, we have incorporated transplantation costs into the analysis and examined the impact of such surgery separately to other categories of severity. Fourth, reporting resource use and standard costs facilitates more transparent translating of study results to other jurisdictions.
The value of our approach in estimating health care costs alongside disease progression is that it will enable future researchers to estimate the long-term impact of new treatments and health services. The model can extrapolate the short-term results of new treatments on outcomes and cost over the longer term. This will enable more timely evaluation of new treatments, with consistent and reliable evidence that reduces the degree of uncertainty in funding decisions. This will become even more important with the promise of new therapies in the R&D pipeline [33, 34] .
